7MM merkel cell carcinoma market reaches $411m in 2023

There are 9,000 new cases of MCC in these markets.

The merkel cell carcinoma (MCC) market was valued at $411m across the 7MM in 2023, according to DelveInsight.

The report estimates around 9,000 new cases of MCC in these markets that include the United States, EU4 (Germany, France, Italy, Spain), the UK, and Japan.

Treatment for localised MCC typically involves surgery and radiation. Advanced cases require systemic therapies such as immune checkpoint inhibitors like avelumab.

Chemotherapy, once a standard treatment for advanced MCC, has become less effective due to its limited long-term benefits, with agents like etoposide and carboplatin offering temporary tumor shrinkage but with high relapse rates and significant side effects.

The MCC market is expected to grow due to increased awareness, early detection, and the approval of new therapies like immune checkpoint inhibitors. Government funding and policies are further driving growth. Emerging treatments and improved diagnostic techniques are anticipated to boost market expansion.

Challenges include the disease's rarity, which limits clinical trial participation and discourages pharmaceutical investment.

Additionall, high immunotherapy costs create access issues, particularly in regions with limited healthcare coverage.

Regulatory hurdles and delayed diagnoses due to low awareness also pose significant barriers to market growth.